Skip to main content
Top
Published in: Breast Cancer Research 1/2010

01-05-2010 | Poster presentation

Regulation of mammary epithelial architecture by PTEN

Authors: JC Lim, L Davidson, NR Weerasinghe, G Zilidis, P Tibarewal, L Spinelli, NR Leslie

Published in: Breast Cancer Research | Special Issue 1/2010

Login to get access

Excerpt

The PTEN tumour suppressor is a core component of the phosphoinositide 3-kinase (PI3K) signalling pathway. PTEN is mutated, deleted, or otherwise silenced in over one-third of breast cancers, with another one-third carrying other activating mutations in the core PI3K signalling pathway, most of these being activating mutations in the p110α catalytic subunit of PI3K itself. The best characterised tumour suppressor roles for PTEN are the suppression of cell growth, survival, proliferation and metabolic deregulation. However, we have found that in three-dimensional cultured mammary epithelial cells, knockdown of PTEN leads to the loss of cell polarity and tissue architecture. PTEN knockdown also causes a dramatic disruption of normal tight junction formation in adherent mammary epithelial cell cultures. Since the deregulation of cell polarity is becoming recognised as a potential driving force behind the formation of some tumours, we have been further studying the mechanisms by which PTEN controls mammary epithelial cell polarity. …
Metadata
Title
Regulation of mammary epithelial architecture by PTEN
Authors
JC Lim
L Davidson
NR Weerasinghe
G Zilidis
P Tibarewal
L Spinelli
NR Leslie
Publication date
01-05-2010
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 1/2010
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2501

Other articles of this Special Issue 1/2010

Breast Cancer Research 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine